1. Scrip
  2. >>Business

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Strong Results But Merck & Co’s Keytruda Also Competing

 
• By Andrew McConaghie

Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.

new gsk logo and hq
GSK needs its own PD1/L1 therapy 'backbone' on which to build future cancer therapy combinations. • Source: GSK

GSK has scored a hit with early results from a pivotal study of its PD-L1 inhibitor cancer therapy Jemperli, showing the drug significantly extended progression-free survival, the primary endpoint, when added to standard-of-care chemotherapy in patients with with primary advanced or recurrent endometrial cancer.

The company believes the interim results from the Phase III RUBY study show that Jemperli (dostarlimab) can “redefine” treatment of the condition, which, once approved in this indication, could give...

More from Business

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

More from Scrip